Acelyrin Inc (NASDAQ:SLRN) is focused on developing Magua map for thyroid eye disease. Positive outcomes include promising proof of concept data, FDA alignment, and strong financial standing. Challenges include trial enrollment delays and uncertainties about future development plans.